Die hypertrophe Kardiomyopathie

Bardy GH, Smith WM, Hood MA et al (2010) An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 363:36–44 Baudhuin LM, Kotzer KE, Kluge ML et al (2015) What is the true prevalence of hypertrophic cardiomyopathy? J Am Coll Cardiol 66:1845–1846 Briasoulis A, Mallikethi-Reddy S, Palla M et al (2015) Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101:1406–1411 Burke MC, Gold MR, Knight BP et al (2015) Safety and efficacy of the totally subcutaneous implantable defibrillator: 2‑year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol 65:1605–1615 Carroll KJ, Makarewich CA, Mcanally J et al (2016) A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci USA 113:338–343 Coats CJ, Hollman A (2008) Hypertrophic cardiomyopathy: lessons from history. Heart 94:1258–1263 Elliott P, Charron P, Blanes JR et al (2016) European Cardiomyopathy pilot registry: EURobservational research programme of the European society of cardiology. Eur Heart J 37:164–173 Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779 Frey N, Luedde M, Katus HA (2011) Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 9:91–100 Frey N, Pieske B, Steven D et al (2016) Kommentar zu den 2014 ESC-Guidelines zur Diagnostik und Therapie der hypertrophen Kardiomyopathie. Kardiologe 10:24–27 Golbus JR, Puckelwartz MJ, Dellefave-Castillo L et al (2014) Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. Circ Cardiovasc Genet 7:751–759 Green EM (2016) A small-molecule inhibitor of sarcomere contractility supresses hypertrophic cardiomyopathy in mice. Science 351(6273):617–621. https://doi.org/10.1126/science.aad3456 Keren A, Syrris P, Mckenna WJ (2008) Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 5:158–168 Lopes LR, Syrris P, Guttmann OP et al (2015) Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart 101:294–301 Lopes LR, Zekavati A, Syrris P et al (2013) Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 50:228–239 Maron BJ, Casey SA, Chan RH et al (2015) Independent Assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol 116:757–764 Maron BJ, Rowin EJ, Casey SA et al (2016) What do patients with hypertrophic cardiomyopathy die from? Am J Cardiol 117:434–435 Maron MS, Hellawell JL, Lucove JC et al (2016) Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol 117:1651–1654 Mearini G, Stimpel D, Geertz B et al (2014) Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat Commun 5:5515 Meder B, Haas J, Keller A et al (2011) Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 4:110–122 O’mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35:2010–2020 Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36:2793–2867 Rapezzi C, Arbustini E, Caforio AL et al (2013) Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:1448–1458 Schulze-Bahr E, Klaassen S, Abdul-Khaliq H et al (2015) Gendiagnostik bei kardiovaskulären Erkrankungen. Kardiologe 9:213–243 Semsarian C, Ingles J, Wilde AA (2015) Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. Eur Heart J 36:1290–1296 Tardiff JC, Carrier L, Bers DM et al (2015) Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res 105:457–470 Veselka J, Jensen MK, Liebregts M et al (2016) Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 37:1517–1523 Vriesendorp PA, Schinkel AF, Liebregts M et al (2015) Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 8:829–835 Wang J, Wang Y, Zou Y et al (2014) Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 16:950–957 Watkins H, Rosenzweig A, Hwang DS et al (1992) Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326:1108–1114 Weinstock J, Bader YH, Maron MS et al (2016) Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience. J Am Heart Assoc 5. https://doi.org/10.1161/JAHA.115.002488